On Tuesday, Citi updated its outlook on UCB SA (Euronext Brussels:UCB) (OTC: UCBJY) shares, raising the price target to €161.00 from €126.00, while reiterating a Buy rating on the stock. The firm's revised forecasts suggest a more optimistic view than the consensus for the years 2024 to 2029, with expectations of 6-60% higher figures.
The upgrade in the price target is driven by a number of factors, including anticipated faster revenue growth and higher peak sales for UCB's products Bimzelx and Rystiggo. These expectations are based on current prescription trends and expanding market developments in health insurance systems.
Additionally, Citi anticipates an atopic dermatitis asset from UCB's pipeline to advance into Phase III clinical trials, which could further boost the company's prospects.
Citi also pointed out the dynamics surrounding Cimzia, a product of UCB, which might benefit from the delayed market entry of competitor Xbrane's biosimilar until at least 2029. Furthermore, a potential revenue increase could arise from a Phase II combination study of Johnson & Johnson's nipocalimab in rheumatoid arthritis.
The financial outlook for UCB is also bolstered by factors such as the underappreciated dynamics of Evenity, which contributes 20-30% of the group's EBITDA, the intellectual property extension for Fintepla until 2033, and royalty revenues from Merck and Sanofi (EPA:SASY) (NASDAQ:SNY)'s oral PCSK9/TNFi pipeline assets.
Citi forecasts a compound annual growth rate (CAGR) for UCB's sales, EBITDA, and EPS from 2024 to 2029 at 11%, 27%, and 33%, respectively. Despite this robust growth outlook, UCB's stock is currently trading at a 2025 price-to-earnings (PE) ratio of 17 times, which is higher than the EU Pharma sector's average PE ratio, excluding Novo Nordisk (NYSE:NVO), which trades around 13 times with a CAGR of 5/6/8%. The new net present value (NPV)-derived price target of €161 reflects a bull-bear valuation range of €224 to €109.
InvestingPro Insights
UCB SA (OTC: UCBJY) has shown a remarkable consistency in shareholder returns, having raised its dividend for an impressive 15 consecutive years. This trend is supported by the company's ability to maintain dividend payments over the last 45 years, signaling a strong commitment to its shareholders. With a market capitalization of $27.63 billion USD, UCB's financial stability is further underscored by its moderate level of debt and a dividend yield of 0.65%.
Investors may also take note of UCB's price performance, with the stock trading near its 52-week high and experiencing a significant price uptick over the last six months. The 6-month price total return stands at a robust 71.23%, highlighting the positive market sentiment towards the company. Additionally, UCB's net income is expected to grow this year, which could provide further momentum for the stock price. These aspects are particularly relevant given Citi's optimistic outlook and price target increase for UCB.
For those looking to delve deeper into UCB's financials and market potential, there are additional InvestingPro Tips available, offering a comprehensive analysis of the company's performance and future prospects. Remember to use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, unlocking access to in-depth insights that can inform your investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.